FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
US6995008B1
(en)
*
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US5736524A
(en)
*
|
1994-11-14 |
1998-04-07 |
Merck & Co.,. Inc. |
Polynucleotide tuberculosis vaccine
|
FR2732895B1
(fr)
*
|
1995-04-11 |
1997-05-16 |
Pasteur Merieux Serums Vacc |
Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
|
US6592877B1
(en)
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6290969B1
(en)
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6338852B1
(en)
|
1995-09-01 |
2002-01-15 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US20070021364A1
(en)
*
|
1995-12-13 |
2007-01-25 |
Hans Herweijer |
Methods for genetic immunization
|
US20020165183A1
(en)
*
|
1999-11-29 |
2002-11-07 |
Hans Herweijer |
Methods for genetic immunization
|
ZA973642B
(en)
*
|
1996-04-26 |
1997-11-25 |
Merck & Co Inc |
DNA vaccine formulations.
|
US5846946A
(en)
*
|
1996-06-14 |
1998-12-08 |
Pasteur Merieux Serums Et Vaccins |
Compositions and methods for administering Borrelia DNA
|
FR2751225B1
(fr)
*
|
1996-07-19 |
1998-11-27 |
Rhone Merieux |
Formule de vaccin polynucleotidique aviaire
|
FR2751228B1
(fr)
*
|
1996-07-19 |
1998-11-20 |
Rhone Merieux |
Vaccin polynucleotidique bovin pour voie intradermique
|
EP2298900A1
(fr)
*
|
1996-09-17 |
2011-03-23 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions et procédés de traitement de maladies intracellulaires
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
US6797276B1
(en)
*
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
AU6148798A
(en)
*
|
1997-02-07 |
1998-08-26 |
Vanderbilt University |
Synthetic genes for recombinant mycobacterium proteins
|
US6261281B1
(en)
*
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
JP2002511396A
(ja)
*
|
1998-04-14 |
2002-04-16 |
メルク エンド カムパニー インコーポレーテッド |
ポリヌクレオチド製剤の無針投与
|
CA2348475A1
(fr)
*
|
1998-11-04 |
2000-05-11 |
Isis Innovation Limited |
Test de diagnostic de la tuberculose
|
US8197461B1
(en)
|
1998-12-04 |
2012-06-12 |
Durect Corporation |
Controlled release system for delivering therapeutic agents into the inner ear
|
US6465633B1
(en)
|
1998-12-24 |
2002-10-15 |
Corixa Corporation |
Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
|
US7022320B1
(en)
|
1999-02-09 |
2006-04-04 |
Powderject Vaccines, Inc. |
Mycobacterium tuberculosis immunization
|
JP4932086B2
(ja)
*
|
1999-04-08 |
2012-05-16 |
インターセル ユーエスエイ、インコーポレイテッド |
経皮的免疫のための乾燥製剤
|
US20070274946A1
(en)
*
|
1999-04-15 |
2007-11-29 |
Norwood Immunoloty, Ltd. |
Tolerance to Graft Prior to Thymic Reactivation
|
US20040241842A1
(en)
*
|
1999-04-15 |
2004-12-02 |
Monash University |
Stimulation of thymus for vaccination development
|
AUPR074500A0
(en)
*
|
2000-10-13 |
2000-11-09 |
Monash University |
Treatment of t cell disorders
|
US20040259803A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Disease prevention by reactivation of the thymus
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
US20050020524A1
(en)
*
|
1999-04-15 |
2005-01-27 |
Monash University |
Hematopoietic stem cell gene therapy
|
US6545127B1
(en)
*
|
1999-06-28 |
2003-04-08 |
Oklahoma Medical Research Foundation |
Catalytically active recombinant memapsin and methods of use thereof
|
US6514948B1
(en)
*
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
US20050100928A1
(en)
*
|
1999-09-16 |
2005-05-12 |
Zycos Inc., A Delaware Corporation |
Nucleic acids encoding polyepitope polypeptides
|
EP2278022A3
(fr)
*
|
1999-11-01 |
2011-05-18 |
Novartis Vaccines and Diagnostics, Inc. |
Vecteurs d'expression, systèmes de transfection et procédé d'utilisation correspondant
|
ATE445643T1
(de)
|
1999-11-18 |
2009-10-15 |
Pharmexa Inc |
Heteroklitische analoga von klasse-i epitopen
|
WO2001045639A2
(fr)
*
|
1999-12-22 |
2001-06-28 |
The Ohio State University Research Foundation |
Procédés de protection contre l'infection létale par le bacillus anthracis
|
FR2804028B1
(fr)
*
|
2000-01-21 |
2004-06-04 |
Merial Sas |
Vaccins adn ameliores pour animaux de rente
|
US6552006B2
(en)
|
2000-01-31 |
2003-04-22 |
The Regents Of The University Of California |
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
|
US20030130217A1
(en)
*
|
2000-02-23 |
2003-07-10 |
Eyal Raz |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
EP1259264A4
(fr)
|
2000-02-23 |
2005-08-31 |
Univ California |
Methode de traitement des maladies intestinales inflammatoires et d'autres formes d'inflammation gastro-intestinale
|
EP1278541A1
(fr)
*
|
2000-04-28 |
2003-01-29 |
The Government of The United States of America, as represented by The Department of Health and Human Services |
Immunogenicite amelioree au moyen d'une combinaison de vaccins a base d'adn et de vecteurs du virus de la vaccine
|
US6590087B1
(en)
*
|
2000-05-25 |
2003-07-08 |
Johns Hopkins University |
whmD, an essential cell division gene from mycobacteria
|
AU2001271963A1
(en)
*
|
2000-07-10 |
2002-01-21 |
Colorado State University Research Foundation |
Mid-life vaccine and methods for boosting anti-mycobacterial immunity
|
CA2415923C
(fr)
|
2000-07-12 |
2011-10-25 |
Agensys, Inc. |
Nouvel antigene tumoral utile dans le diagnostic et le traitement de cancers de la vessie, de l'ovaire, du poumon et du rein
|
EP1313850B1
(fr)
|
2000-08-28 |
2008-08-06 |
Agensys, Inc. |
Acide nucleique et proteine correspondante denommes 85p1b3 utilises dans le traitement et la detection de cancers
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
EP1911461B1
(fr)
|
2000-10-19 |
2011-12-07 |
Epimmune Inc. |
Peptides de liaisons HLA de classe I et II et leurs utilisations
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
ES2310201T3
(es)
*
|
2001-02-13 |
2009-01-01 |
Government Of The United States Of America, As Represented By The Secretary Of The Army |
Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros.
|
US7491394B2
(en)
|
2001-02-15 |
2009-02-17 |
The Board Of Trustees Of The University Of Illinois |
Cytotoxic factors for modulating cell death
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
AU2002303247B2
(en)
*
|
2001-04-06 |
2005-03-24 |
Dana-Farber Cancer Institute |
Chemotherapeutic induction of Egr-1 promoter activity
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
CA2443123A1
(fr)
|
2001-04-10 |
2002-10-24 |
Agensys, Inc. |
Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
|
US7013940B2
(en)
*
|
2001-04-19 |
2006-03-21 |
Michelin Recherche Et Technique S.A. |
Device for attenuating cavity noise in a tire and wheel
|
CA2448097A1
(fr)
|
2001-05-22 |
2002-11-28 |
University Of Chicago |
Arn polymerase dependant de l'adn a brin unique de virion n4
|
WO2003015716A2
(fr)
*
|
2001-08-13 |
2003-02-27 |
Ige Therapeutics, Inc. |
Vaccins d'immunoglobuline e et leurs procedes d'utilisation
|
ES2532757T3
(es)
|
2001-09-06 |
2015-03-31 |
Agensys, Inc. |
Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
|
CN100417419C
(zh)
*
|
2001-10-26 |
2008-09-10 |
贝勒医学院 |
改变个体的瘦体重和骨特性的组合物和方法
|
US7241744B2
(en)
*
|
2001-12-11 |
2007-07-10 |
Baylor College Of Medicine |
Treating anemia in subjects by administration of plasmids encoding growth hormone releasing hormone
|
JP2005527490A
(ja)
*
|
2002-01-18 |
2005-09-15 |
イノヴィオ アーエス |
筋肉内投与のための二重特異性抗体dna構築物
|
ATE443133T1
(de)
|
2002-02-01 |
2009-10-15 |
Life Technologies Corp |
Oligonukleotidzusammensetzungen mit verbesserter effizienz
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20050267025A1
(en)
*
|
2002-02-01 |
2005-12-01 |
Ho John L |
Compositions and methods for treatment of infectious and inflammatory diseases
|
US20030166282A1
(en)
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
US20030199012A1
(en)
*
|
2002-02-01 |
2003-10-23 |
Ho John L. |
Compositions and methods for treatment of infectious and inflammatory diseases
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
EP2258712A3
(fr)
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
|
AU2003218181A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Multicell Immunotherapeutics, Inc. |
Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
|
US7078037B2
(en)
*
|
2002-04-19 |
2006-07-18 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
|
US20060094006A1
(en)
*
|
2002-05-01 |
2006-05-04 |
Genoveffa Franchini |
Immunotherapy regimens in hiv-infected patients
|
CN100418981C
(zh)
|
2002-06-10 |
2008-09-17 |
瓦西尼斯公司 |
在乳腺癌和膀胱癌中差异表达的基因及编码多肽
|
US20090110702A1
(en)
|
2002-07-12 |
2009-04-30 |
The Johns Hopkins University |
Mesothelin Vaccines and Model Systems and Control of Tumors
|
WO2004006837A2
(fr)
*
|
2002-07-12 |
2004-01-22 |
The Johns Hopkins University |
Vaccins a la mesotheline et systemes de modele
|
US9200036B2
(en)
|
2002-07-12 |
2015-12-01 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
ATE497774T1
(de)
|
2002-07-15 |
2011-02-15 |
Univ Texas |
Screening kombinatorischer proteinbibliotheken mittels periplasmatischer expression
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
KR101170653B1
(ko)
|
2002-08-12 |
2012-08-03 |
제네렉스, 인코포레이티드 |
폭스바이러스 및 암과 관련된 방법 및 조성물
|
US20040081653A1
(en)
|
2002-08-16 |
2004-04-29 |
Raitano Arthur B. |
Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
|
JP2006503914A
(ja)
*
|
2002-10-21 |
2006-02-02 |
エムジーアイ ファーマ バイオロジックス インコーポレイテッド |
ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
|
AU2002352976B2
(en)
|
2002-11-27 |
2007-11-08 |
Agensys, Inc. |
Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
|
EP1903056A3
(fr)
|
2002-12-10 |
2008-05-07 |
Idm Pharma, Inc. |
Peptides se liant au HLA-A1, -A2, -A3, -A24, -B7 and -B44 et comprenant des épitopes d'antigène associé à une tumeur, et compositions les comprenant
|
WO2004072263A2
(fr)
|
2003-02-10 |
2004-08-26 |
Agensys, Inc. |
Acide nucleique et proteine correspondante dite 158p1d7, utiles pour le traitement et la detection de cancers de la vessie et autres
|
US7262027B2
(en)
*
|
2003-03-14 |
2007-08-28 |
Medical College Of Ohio |
Polypeptide and DNA immunization against Coccidioides spp. infections
|
WO2004087877A2
(fr)
*
|
2003-03-26 |
2004-10-14 |
Astral Inc. |
Motif d'arn selectionne destine a induire la mort cellulaire et/ou l'apoptose
|
TW200424214A
(en)
*
|
2003-04-21 |
2004-11-16 |
Advisys Inc |
Plasmid mediated GHRH supplementation for renal failures
|
WO2004098497A2
(fr)
*
|
2003-04-28 |
2004-11-18 |
Genencor International, Inc. |
Epitopes cd4+ du papillomavirus
|
PT1629088E
(pt)
|
2003-05-30 |
2012-04-10 |
Agensys Inc |
Variantes de antigénio de células estaminais de próstata (psca) e subsequências das mesmas
|
US20060240039A1
(en)
*
|
2003-06-13 |
2006-10-26 |
Isis Innovation Limited |
Vaccines
|
US20070224615A1
(en)
*
|
2003-07-09 |
2007-09-27 |
Invitrogen Corporation |
Methods for assaying protein-protein interactions
|
CN1894581B
(zh)
|
2003-07-09 |
2012-02-01 |
生命技术公司 |
检测蛋白-蛋白相互作用的方法
|
NZ545364A
(en)
*
|
2003-09-05 |
2009-06-26 |
Genencor Int |
HPV CD8+ T-cell epitopes
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
EP1716173B8
(fr)
*
|
2004-02-11 |
2012-06-27 |
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. |
Proteines de fusion a antigene carcinoembryonique et utilisations de ces proteines
|
WO2005090559A1
(fr)
*
|
2004-03-18 |
2005-09-29 |
Fred Hutchinson Cancer Research Center |
Procedes et compositions impliquant des regions de promoteur s-ship
|
MXPA06013834A
(es)
|
2004-05-28 |
2007-03-01 |
Agensys Inc |
Anticuerpos y moleculas relacionadas que enlazan a proteinas psca.
|
WO2006017279A2
(fr)
*
|
2004-07-12 |
2006-02-16 |
Board Of Regents, The University Of Texas System |
Procédés et compositions concernant l'identification des interactions protéine-protéine
|
US7572600B2
(en)
|
2004-08-04 |
2009-08-11 |
Chemocentryx, Inc. |
Enzymatic activities in chemokine-mediated inflammation
|
EP2281888B1
(fr)
|
2004-11-12 |
2015-01-07 |
Asuragen, Inc. |
Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
|
MX2007005256A
(es)
|
2004-11-16 |
2008-03-11 |
Crucell Holland Bv |
Vacunas multivalentes que comprenden vectores virales recombinantes.
|
WO2006060332A2
(fr)
*
|
2004-12-01 |
2006-06-08 |
Aeras Global Tb Vaccine Foundation |
Electroporation of mycobacterium et surexpression d'antigenes dans des mycobacteries
|
CA2597404A1
(fr)
*
|
2005-02-11 |
2006-08-17 |
Merck & Co. Inc. |
Vecteurs d'adenovirus de serotype 26, acide nucleique et virus produits par ces vecteurs
|
ES2364670T3
(es)
|
2005-02-25 |
2011-09-12 |
Oncotherapy Science, Inc. |
Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk.
|
DK2095822T3
(da)
|
2005-02-28 |
2014-01-13 |
Oncotherapy Science Inc |
Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
|
RU2413735C2
(ru)
|
2005-03-31 |
2011-03-10 |
Эдженсис, Инк. |
Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
|
RS54088B1
(en)
|
2005-07-25 |
2015-10-30 |
Emergent Products Development Seattle Llc |
B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
|
JP5095603B2
(ja)
|
2005-07-27 |
2012-12-12 |
オンコセラピー・サイエンス株式会社 |
結腸癌関連遺伝子tom34
|
US20070092517A1
(en)
*
|
2005-08-10 |
2007-04-26 |
Oklahoma Medical Research Foundation |
Truncated memapsin 2 compositions and treatments
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
EP1933857A2
(fr)
*
|
2005-09-07 |
2008-06-25 |
Jennerex Biotherapeutics ULC |
Traitement systemique de cancers metastasiques et/ou systemiquement dissemines a l'aide de poxvirus exprimant le gm-csf
|
US7919258B2
(en)
*
|
2005-10-07 |
2011-04-05 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Rapid tuberculosis detection method
|
EP1998800A2
(fr)
|
2006-01-18 |
2008-12-10 |
University Of Chicago |
Compositions et procédés se rapportant à des protéines de bactéries staphylococciques
|
EP2441469A1
(fr)
*
|
2006-03-14 |
2012-04-18 |
Oregon Health and Science University |
Méthode pour produire une reponse contre la tuberculose
|
GB0605474D0
(en)
*
|
2006-03-17 |
2006-04-26 |
Isis Innovation |
Clinical correlates
|
KR101571027B1
(ko)
*
|
2006-06-12 |
2015-11-23 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
효과기 기능을 갖는 단일쇄 다가 결합 단백질
|
EP2069791B1
(fr)
|
2006-07-27 |
2012-01-25 |
University of Maryland, Baltimore |
Recepteur cellulaire du facteur antiproliferation
|
CN105769931B
(zh)
|
2006-09-15 |
2021-04-27 |
渥太华医院研究机构 |
溶瘤弹状病毒
|
EP2687540A1
(fr)
|
2006-10-17 |
2014-01-22 |
Oncotherapy Science, Inc. |
Vaccins de peptide pour cancers exprimant les polypeptides MPHOSPH1 ou DEPDC1
|
US8753840B2
(en)
*
|
2006-10-20 |
2014-06-17 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Modified cyanobacteria
|
US8067179B2
(en)
|
2006-11-30 |
2011-11-29 |
Research Development Foundation |
Immunoglobulin libraries
|
TWI610939B
(zh)
|
2007-02-21 |
2018-01-11 |
腫瘤療法 科學股份有限公司 |
表現腫瘤相關抗原之癌症的胜肽疫苗
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
TW201425333A
(zh)
|
2007-04-11 |
2014-07-01 |
Oncotherapy Science Inc |
腫瘤血管內皮標誌8胜肽及包含此胜肽之疫苗
|
EP2155789B1
(fr)
|
2007-05-01 |
2013-07-24 |
Research Development Foundation |
Banques d'immunoglobulines fc
|
EP2167130A2
(fr)
*
|
2007-07-06 |
2010-03-31 |
Trubion Pharmaceuticals, Inc. |
Peptides de liaison comprenant un domaine de liaison spécifique c-terminal
|
CA2697538C
(fr)
|
2007-08-31 |
2019-02-12 |
University Of Chicago |
Procedes et compositions associees pour immuniser contre des maladies et des etats staphylococciques des poumons
|
WO2009059011A2
(fr)
|
2007-11-01 |
2009-05-07 |
Mayo Foundation For Medical Education And Research |
Peptides de liaison hla-dr et leurs utilisations
|
CA2711499C
(fr)
|
2008-01-10 |
2018-09-25 |
Research Development Foundation |
Vaccins et diagnostics pour les ehrlichioses
|
NZ586746A
(en)
*
|
2008-01-23 |
2012-07-27 |
Righospitalet |
Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
|
CN102066937A
(zh)
|
2008-01-25 |
2011-05-18 |
P53股份有限公司 |
P53生物标记物
|
AU2009225665B9
(en)
|
2008-03-17 |
2015-01-15 |
The Scripps Research Institute |
Combined chemical and genetic approaches for generation of induced pluripotent stem cells
|
WO2009117134A2
(fr)
*
|
2008-03-21 |
2009-09-24 |
National Institutes Of Health |
Vaccins génétiques aérolisés et procédés d'utilisation
|
NZ588671A
(en)
*
|
2008-04-11 |
2012-11-30 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
US20110129499A1
(en)
|
2008-05-19 |
2011-06-02 |
Paulo Maciag |
Dual delivery system for heterologous antigens
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
DK2297307T3
(en)
|
2008-06-04 |
2016-07-25 |
Cellular Dynamics Int Inc |
PROCEDURES FOR THE MANUFACTURE OF IPS CELLS USING NON-VIRAL METHODS
|
CN101896196A
(zh)
*
|
2008-07-25 |
2010-11-24 |
生物技术部 |
构建用于抗利什曼病和结核病的疫苗开发的dna嵌合体
|
CA2734128A1
(fr)
|
2008-08-12 |
2010-02-18 |
Cellular Dynamics International, Inc. |
Procedes de production de cellules ips
|
AU2009282625A1
(en)
|
2008-08-18 |
2010-02-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Derivatives of APF and methods of use
|
WO2010023877A1
(fr)
|
2008-08-27 |
2010-03-04 |
Oncotherapy Science, Inc. |
Prmt1 pour gènes cibles du traitement et du diagnostic du cancer
|
EP2341929B1
(fr)
|
2008-10-06 |
2017-01-25 |
University Of Chicago |
Compositions et procédés associés aux protéines bactériennes emp
|
JP2012506858A
(ja)
*
|
2008-10-23 |
2012-03-22 |
インターベット インターナショナル ベー. フェー. |
Lawsoniaintracellularisワクチン
|
TWI500932B
(zh)
|
2008-12-05 |
2015-09-21 |
Oncotherapy Science Inc |
Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗
|
JP5651125B2
(ja)
|
2008-12-10 |
2015-01-07 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Mek阻害剤に対する耐性を付与するmek突然変異
|
EP3312269A1
(fr)
|
2008-12-17 |
2018-04-25 |
The Scripps Research Institute |
Génération et entretien de cellules souches
|
US8492133B2
(en)
|
2009-01-20 |
2013-07-23 |
Ramot At Tel Aviv University, Ltd. |
MIR-21 promoter driven targeted cancer therapy
|
TWI469791B
(zh)
|
2009-02-18 |
2015-01-21 |
Oncotherapy Science Inc |
Foxm1胜肽以及含此胜肽之疫苗
|
DK2408913T3
(en)
|
2009-03-18 |
2017-03-06 |
Oncotherapy Science Inc |
NEIL3 PEPTIDES AND VACCINES CONTAINING THESE
|
WO2011005341A2
(fr)
|
2009-04-03 |
2011-01-13 |
University Of Chicago |
Compositions et méthodes associées aux variants de la protéine a (spa)
|
DK3061766T3
(da)
|
2009-04-28 |
2020-03-16 |
Univ Vanderbilt |
Sammensætninger og fremgangsmåder til behandlingen af sygdomme der involverer epitelcelleapoptose
|
TWI507204B
(zh)
|
2009-05-26 |
2015-11-11 |
Oncotherapy Science Inc |
Cdc45l胜肽與含此胜肽之疫苗
|
CA2764373C
(fr)
|
2009-06-05 |
2019-11-19 |
Cellular Dynamics International, Inc. |
Reprogrammation de cellules t et de cellules hematophietiques
|
CA2772298A1
(fr)
|
2009-08-26 |
2011-03-03 |
Research Development Foundation |
Procedes pour creer des banques d'anticorps
|
ES2671570T3
(es)
|
2009-09-14 |
2018-06-07 |
Sillajen Biotherapeutics, Inc. |
Terapia combinada contra el cáncer con virus oncolítico de vaccinia
|
US9175070B2
(en)
|
2009-09-25 |
2015-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to HIV-1 and their use
|
CA2775720A1
(fr)
*
|
2009-09-30 |
2011-04-07 |
Saint Louis University |
Peptides declenchant des reponses hetero sous-typiques des lymphocytes t contre la grippe
|
EP3235901B1
(fr)
|
2009-10-16 |
2022-12-21 |
The Scripps Research Institute |
Induction de cellules pluripotentes
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
MX337062B
(es)
|
2009-12-10 |
2016-02-11 |
Ottawa Hospital Res Inst |
Rabdovirus oncolítico.
|
TW201136604A
(en)
|
2009-12-14 |
2011-11-01 |
Oncotherapy Science Inc |
TMEM22 peptides and vaccines including the same
|
US10080799B2
(en)
|
2010-02-12 |
2018-09-25 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions related to glycoprotein-immunoglobulin fusions
|
RU2571930C2
(ru)
|
2010-02-25 |
2015-12-27 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Мутации braf, обеспечивающие резистентность к ингибиторам braf
|
US20130052221A1
(en)
|
2010-02-26 |
2013-02-28 |
The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services |
Dna-protein vaccination protocols
|
EP3214174B1
(fr)
|
2010-03-04 |
2019-10-16 |
InteRNA Technologies B.V. |
Molécule d'arnmi définie par sa source et son diagnostic et utilisations thérapeutiques dans des maladies ou des pathologies associées à l'emt
|
CA2792910A1
(fr)
|
2010-03-11 |
2011-09-15 |
Yusuke Nakamura |
Peptides hjurp et vaccins les comprenant
|
JP5909482B2
(ja)
|
2010-03-31 |
2016-04-26 |
ザ スクリプス リサーチ インスティテュート |
細胞の再プログラム
|
TW201627003A
(zh)
|
2010-04-02 |
2016-08-01 |
腫瘤療法 科學股份有限公司 |
Ect2胜肽及含此胜肽之疫苗
|
EP2555794A4
(fr)
|
2010-04-05 |
2014-01-15 |
Univ Chicago |
COMPOSITIONS ET PROCÉDÉS LIÉS AUX ANTICORPS DE LA PROTÉINE A (SpA) EN TANT QUE AMPLIFICATEUR DE LA RÉPONSE IMMUNITAIRE
|
US9249195B2
(en)
|
2010-04-07 |
2016-02-02 |
Vanderbilt University |
Reovirus vaccines and methods of use therefor
|
DK2560672T3
(en)
|
2010-04-19 |
2014-03-17 |
Res Dev Foundation |
RTEF-1 variants and their uses
|
CN103097526B
(zh)
|
2010-06-09 |
2015-09-16 |
达纳-法伯癌症研究所公司 |
赋予针对raf和mek抑制剂的抗性的mek1突变
|
EP2580320B1
(fr)
|
2010-06-14 |
2018-08-01 |
The Scripps Research Institute |
Reprogrammation de cellules pour leur conférer un nouveau destin
|
CA2802249A1
(fr)
|
2010-06-15 |
2011-12-22 |
Cellular Dynamics International, Inc. |
Generation de cellules souches pluripotentes induites a partir de petits volumes de sang peripherique
|
US20110312001A1
(en)
|
2010-06-15 |
2011-12-22 |
Emile Nuwaysir |
Compendium of ready-built stem cell models for interrogation of biological response
|
AU2011274367B2
(en)
|
2010-07-02 |
2015-04-23 |
The University Of Chicago |
Compositions and methods related to protein A (SpA) variants
|
AU2011274619B2
(en)
|
2010-07-06 |
2016-11-10 |
Interna Technologies Bv |
miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
|
EP2591093B1
(fr)
|
2010-07-07 |
2018-11-28 |
FUJIFILM Cellular Dynamics, Inc. |
Production de cellules endothéliales par programmation
|
CA2806858C
(fr)
|
2010-08-04 |
2021-06-15 |
Cellular Dynamics International, Inc. |
Reprogrammation des lymphocytes b immortalises
|
EP2614074A1
(fr)
|
2010-09-09 |
2013-07-17 |
The University of Chicago |
Procédés et compositions impliquant des antigènes staphylococciques protecteurs
|
EP3536337A1
(fr)
|
2010-09-22 |
2019-09-11 |
The Regents of the University of Colorado, a body corporate |
Applications thérapeutiques de smad7
|
US20130267029A1
(en)
|
2010-10-01 |
2013-10-10 |
Fundacion Centro Nacional de Ivestigaciones Oncologicas, Carlos |
Manipulation of stem cell function by p53 isoforms
|
WO2012138377A2
(fr)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
Utilisation de vecteurs de vaccin de listeria pour renverser l'insensibilité au vaccin chez des individus infectés par des parasites
|
AU2011349446C1
(en)
|
2010-12-22 |
2016-01-21 |
Fate Therapauetics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
|
KR101942237B1
(ko)
|
2011-01-04 |
2019-01-25 |
신라젠(주) |
종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
|
EP2474617A1
(fr)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR pour traiter une nouvelle angiogenèse
|
RU2539035C2
(ru)
*
|
2011-01-13 |
2015-01-10 |
Амир Закиевич Максютов |
Профилактическая или терапевтическая полиэпитопная противотуберкулезная вакцинная конструкция, обеспечивающая индукцию клеточного иммунного ответа cd4+ или cd8+ т-лимфоцитов
|
WO2012109133A1
(fr)
|
2011-02-07 |
2012-08-16 |
Research Development Foundation |
Polypeptides fc modifiés d'immunoglobuline
|
WO2012109208A2
(fr)
|
2011-02-08 |
2012-08-16 |
Cellular Dynamics International, Inc. |
Production de précurseurs hématopoïétiques obtenus par programmation
|
CA2829960A1
(fr)
|
2011-03-11 |
2012-09-20 |
John Rothman |
Adjuvants a base de listeria
|
WO2012136653A1
(fr)
|
2011-04-08 |
2012-10-11 |
Novvac Aps |
Protéines et acides nucléiques utiles dans des vaccins ciblant le staphylococcus aureus
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
ES2931180T3
(es)
|
2011-05-19 |
2022-12-27 |
Fund Publica Andaluza Progreso Y Salud |
Sistema de tipo Tet-on lentivírico de promotor dual muy inducible
|
US9364532B2
(en)
|
2011-06-08 |
2016-06-14 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions and methods for glioblastoma treatment
|
JP2014520551A
(ja)
|
2011-07-11 |
2014-08-25 |
セルラー ダイナミクス インターナショナル, インコーポレイテッド |
細胞のリプログラミング方法およびゲノムの改変方法
|
ES2613808T3
(es)
|
2011-07-29 |
2017-05-26 |
Oncotherapy Science, Inc. |
Péptido derivado de ERAP1 y uso del mismo
|
KR102015648B1
(ko)
|
2011-08-12 |
2019-08-28 |
온코세라피 사이언스 가부시키가이샤 |
Mphosph1 펩티드 및 이를 포함한 백신
|
CN103906535B
(zh)
|
2011-08-15 |
2017-07-14 |
芝加哥大学 |
与葡萄球菌蛋白a的抗体相关的组合物和方法
|
WO2013026015A1
(fr)
|
2011-08-18 |
2013-02-21 |
Dana-Farber Cancer Institute, Inc. |
Pièges de ligand de muc1 pour l'utilisation dans le traitement de cancers
|
JP2013046596A
(ja)
*
|
2011-08-29 |
2013-03-07 |
Alpha-Nano-Medica Co Ltd |
新規な複合体、それを含有する医薬及び癌の治療方法
|
WO2013053899A1
(fr)
|
2011-10-12 |
2013-04-18 |
Moeller Niels Iversen |
Peptides dérivés de campylobacter jejuni et leur utilisation en vaccination
|
SG10201608552WA
(en)
|
2011-10-28 |
2016-12-29 |
Oncotherapy Science Inc |
Topk Peptides And Vaccines Including The Same
|
ES2688619T3
(es)
|
2011-12-22 |
2018-11-05 |
Interna Technologies B.V. |
MiARN para tratar el cáncer de cabeza y de cuello
|
WO2013138337A1
(fr)
|
2012-03-12 |
2013-09-19 |
Advaxis |
Inhibition de la fonction des cellules suppresseurs après traitement par un vaccin à base de listeria
|
JP6251730B2
(ja)
|
2012-04-26 |
2017-12-20 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
黄色ブドウ球菌(staphylococcusaureus)疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
|
JP6670106B2
(ja)
|
2012-04-26 |
2020-03-18 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
ブドウ球菌コアグラーゼ抗原およびその使用方法
|
EP2872530A4
(fr)
|
2012-07-10 |
2016-04-06 |
Oncotherapy Science Inc |
Peptides épitopes du kif20a pour cellules th1 et vaccins les contenant
|
JP6255594B2
(ja)
|
2012-07-10 |
2018-01-10 |
オンコセラピー・サイエンス株式会社 |
Th1細胞のLY6Kエピトープペプチドおよびこれを含有するワクチン
|
DK2895600T3
(da)
|
2012-09-11 |
2020-04-27 |
Onco Therapy Science Inc |
Ube2t-peptider og vacciner, der indeholder disse
|
EP2912058A1
(fr)
|
2012-10-23 |
2015-09-02 |
The Board of Regents of The University of Texas System |
Anticorps avec des domaines fc d'igg modifiés
|
WO2014072357A1
(fr)
|
2012-11-06 |
2014-05-15 |
Interna Technologies B.V. |
Association médicamenteuse utilisable en vue du traitement de maladies ou d'affections associées au mélanome ou à l'activation de la voie de signalisation braf
|
WO2014116721A1
(fr)
|
2013-01-22 |
2014-07-31 |
The Arizona Board Of Regents For And On Behalf Of Arizona State University |
Vecteur geminiviral pour l'expression du rituximab
|
ES2904803T3
(es)
|
2013-02-20 |
2022-04-06 |
Regeneron Pharma |
Modificación genética de ratas
|
AU2014221143B2
(en)
|
2013-02-21 |
2019-02-07 |
Turnstone Limited Partnership |
Vaccine composition
|
WO2014130770A1
(fr)
|
2013-02-22 |
2014-08-28 |
Cellular Dynamics International, Inc. |
Production d'hépatocytes par programmation aller par génie génétique et chimique combiné
|
WO2014134144A1
(fr)
|
2013-02-28 |
2014-09-04 |
The General Hospital Corporation |
Compositions de profilage de miarn et procédés d'utilisation
|
WO2014138670A1
(fr)
|
2013-03-08 |
2014-09-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Produits thérapeutiques ptd-smad7
|
TWI658049B
(zh)
|
2013-03-12 |
2019-05-01 |
腫瘤療法 科學股份有限公司 |
Kntc2胜肽及含此胜肽之疫苗
|
ES2751423T3
(es)
*
|
2013-03-15 |
2020-03-31 |
Univ Geneve |
Vacunas antimicobacterianas
|
CN105324128B
(zh)
|
2013-03-27 |
2020-09-01 |
免疫疫苗技术有限公司 |
用于改善存活蛋白疫苗在癌症治疗中的功效的方法
|
RU2520078C1
(ru)
*
|
2013-04-25 |
2014-06-20 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) |
СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
|
WO2015035395A1
(fr)
|
2013-09-09 |
2015-03-12 |
Figene, Llc |
Thérapie génique pour la régénération de cellules de type chondrocytes ou cartilagineuses
|
EP3065775B1
(fr)
|
2013-11-08 |
2020-09-30 |
The Board of Regents of the University of Texas System |
Anticorps vh4 dirigés contre les astrocytes et les neurones de la matière grise
|
CA2929555A1
(fr)
|
2013-11-08 |
2015-05-14 |
Baylor Research Institute |
La localisation nucleaire de glp-1 stimule la regeneration myocardique et entraine la regression d'une insuffisance cardiaque
|
US20160368952A1
(en)
|
2013-12-03 |
2016-12-22 |
Evaxion Biotech Aps |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
CA2938111C
(fr)
|
2014-01-29 |
2024-02-06 |
Dana-Farber Cancer Institute, Inc. |
Anticorps contre le domaine extracellulaire de muc1-c (muc1-c/ecd)
|
EP3105332A4
(fr)
|
2014-02-14 |
2018-01-10 |
University of Utah Research Foundation |
Méthodes et compositions pour l'inhibition de la rétinopathie associée à la prématurité
|
EP3110836A1
(fr)
|
2014-02-25 |
2017-01-04 |
Research Development Foundation |
Peptides sty pour l'inhibition de l'angiogenèse
|
EP3805369A1
(fr)
|
2014-03-04 |
2021-04-14 |
Fate Therapeutics, Inc. |
Procédés améliorés de reprogrammation et plateformes de culture cellulaire
|
US20170107486A1
(en)
|
2014-04-21 |
2017-04-20 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
EP3981416B1
(fr)
|
2014-08-04 |
2024-03-20 |
OncoTherapy Science, Inc. |
Peptide dérivé de koc1 et vaccin le comportant
|
BR112017002193A2
(pt)
|
2014-08-04 |
2017-11-21 |
Oncotherapy Science Inc |
peptídeo derivado de urlc10 e vacina contendo o mesmo
|
CN113321704A
(zh)
|
2014-08-04 |
2021-08-31 |
肿瘤疗法科学股份有限公司 |
Cdca1衍生的肽和含有它们的疫苗
|
WO2016025510A1
(fr)
|
2014-08-12 |
2016-02-18 |
Rappolee Daniel A |
Systèmes et méthodes de détection du stress dans les cellules souches et leurs utilisations
|
EP3218002B1
(fr)
|
2014-11-13 |
2020-08-19 |
Evaxion Biotech ApS |
Peptides dérivés d'acinetobacter baumannii et leur utilisation en vaccination
|
CN107531736B
(zh)
|
2015-01-06 |
2022-04-15 |
免疫疫苗科技公司 |
脂质a模拟物、其制备方法和用途
|
EP3244918A2
(fr)
|
2015-01-12 |
2017-11-22 |
Evaxion Biotech ApS |
Protéines et acides nucléiques utiles dans des vaccins ciblant le klebsiella pneumoniae
|
WO2016120697A1
(fr)
|
2015-01-28 |
2016-08-04 |
Sabic Global Technologies B.V. |
Procédés et compositions pour une production à haut rendement de biocarburant et/ou de biomasse
|
WO2016130516A1
(fr)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Polypeptides ayant un domaine fc d'immunoglobuline modifié manifestant une activation du complément améliorée
|
WO2016134293A1
(fr)
|
2015-02-20 |
2016-08-25 |
Baylor College Of Medicine |
Inactivation de p63 pour le traitement de l'insuffisance cardiaque
|
US20180346520A1
(en)
|
2015-05-13 |
2018-12-06 |
The United States Of America As Represented By The Secretary Of The Department Of Health And |
Methods and compositions for inducing an immune response using conserved element constructs
|
WO2016196366A1
(fr)
|
2015-05-29 |
2016-12-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extension de durée de vie réplicative dans des maladies de vieillissement prématuré à l'aide d'isoformes p53
|
US20180201656A1
(en)
|
2015-07-04 |
2018-07-19 |
Evaxion Biotech Aps |
Proteins and nucleic acids useful in vaccines targeting Pseudomonas Aeruginosa
|
WO2017040380A2
(fr)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Variants de fc d'anticorps modifiés
|
CA2999138C
(fr)
|
2015-09-21 |
2024-05-21 |
Aptevo Research And Development Llc |
Polypeptides de liaison a cd3
|
US11242365B2
(en)
|
2015-10-08 |
2022-02-08 |
Oncotherapy Science, Inc. |
FOXM1-derived peptide, and vaccine including same
|
AU2016338680B2
(en)
|
2015-10-16 |
2022-11-17 |
Fate Therapeutics, Inc. |
Platform for the induction and maintenance of ground state pluripotency
|
AU2016342183B2
(en)
|
2015-10-20 |
2022-03-03 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for directed differentiation of pluripotent stem cells to immune cells
|
CN108463548B
(zh)
|
2015-10-30 |
2023-04-18 |
加利福尼亚大学董事会 |
由干细胞产生t细胞的方法及使用所述t细胞的免疫治疗方法
|
WO2017079202A1
(fr)
|
2015-11-02 |
2017-05-11 |
Board Of Regents, The University Of Texas System |
Méthodes d'activation de cd40 et blocage de points de contrôle immunitaires
|
CA3004530A1
(fr)
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methodes et compositions comprenant une therapie genique suppressive de tumeur et le blocage du point de controle immunitaire pour le traitement du cancer
|
DK3373968T3
(da)
|
2015-11-09 |
2024-05-13 |
Childrens Hospital Philadelphia |
Glypican 2 som en tumormarkør og terapeutisk mål
|
WO2017144523A1
(fr)
|
2016-02-22 |
2017-08-31 |
Evaxion Biotech Aps |
Protéines et acides nucléiques utiles dans des vaccins ciblant staphylococcus aureus
|
WO2017168348A1
(fr)
|
2016-03-31 |
2017-10-05 |
Baylor Research Institute |
Protéine 8 de type angiopoïétine (angptl8)
|
WO2017216384A1
(fr)
|
2016-06-17 |
2017-12-21 |
Evaxion Biotech Aps |
Vaccination ciblant ichthyophthirius multifiliis
|
EP3474889A4
(fr)
*
|
2016-06-22 |
2020-04-29 |
International AIDS Vaccine Initiative, Inc. |
Vecteurs de cytomégalovirus de recombinaison utilisés comme vaccins contre la tuberculose
|
WO2017220787A1
(fr)
|
2016-06-24 |
2017-12-28 |
Evaxion Biotech Aps |
Vaccin contre l'infection provoquée par aeromonas salmonicida
|
AU2017290805B2
(en)
|
2016-07-01 |
2023-11-16 |
Research Development Foundation |
Elimination of proliferating cells from stem cell-derived grafts
|
WO2018015575A1
(fr)
|
2016-07-22 |
2018-01-25 |
Evaxion Biotech Aps |
Protéines chimériques pour induire une immunité vis-à-vis d'une infection à s. aureus
|
US9963498B2
(en)
|
2016-08-18 |
2018-05-08 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
|
AU2017319702A1
(en)
|
2016-09-02 |
2019-04-11 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
BR112019006910A2
(pt)
|
2016-10-05 |
2019-07-02 |
Fujifilm Cellular Dynamics Inc |
métodos para diferenciação dirigida de células-tronco pluripotentes para células imunes homozigóticas de hla
|
US10961505B2
(en)
|
2016-10-05 |
2021-03-30 |
FUJIFILM Cellular Dynamics, Inc. |
Generating mature lineages from induced pluripotent stem cells with MECP2 disruption
|
EP3551226A1
(fr)
|
2016-12-12 |
2019-10-16 |
MultiVir Inc. |
Méthodes et compositions comprenant une thérapie génique virale et un inhibiteur de point de contrôle immunitaire pour le traitement et la prévention du cancer et des maladies infectieuses
|
US11718648B2
(en)
|
2017-01-05 |
2023-08-08 |
Evaxion Biotech A/S |
Vaccines targeting Pseudomonas aeruginosa
|
AU2018254442B2
(en)
|
2017-04-18 |
2024-03-28 |
FUJIFILM Cellular Dynamics, Inc. |
Antigen-specific immune effector cells
|
CN111566212A
(zh)
|
2017-11-03 |
2020-08-21 |
因特尔纳技术有限公司 |
miRNA分子,等同物,安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生
|
WO2019099493A1
(fr)
|
2017-11-14 |
2019-05-23 |
Henry Ford Health System |
Compositions destinées à être utilisées dans le traitement et la prévention de troubles cardiovasculaires résultant d'une lésion cérébrovasculaire
|
CN112313339A
(zh)
|
2018-01-05 |
2021-02-02 |
渥太华医院研究所 |
修饰的牛痘载体
|
WO2019145399A1
(fr)
|
2018-01-24 |
2019-08-01 |
Evaxion Biotech Aps |
Vaccins pour la prophylaxie d'infections par s. aureus
|
KR20200135986A
(ko)
|
2018-03-19 |
2020-12-04 |
멀티비르 인코포레이티드 |
종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
|
WO2019186274A2
(fr)
|
2018-03-30 |
2019-10-03 |
University Of Geneva |
Constructions d'expression de micro arn et leurs utilisations
|
TW202023581A
(zh)
|
2018-08-02 |
2020-07-01 |
日商腫瘤療法 科學股份有限公司 |
來自cdca1的胜肽及含有此的疫苗
|
CN113164556A
(zh)
|
2018-08-30 |
2021-07-23 |
特纳亚治疗股份有限公司 |
用心肌蛋白和ascl1进行的心脏细胞重编程
|
WO2020069313A2
(fr)
|
2018-09-28 |
2020-04-02 |
Henry Ford Health System |
Utilisation de vésicules extracellulaires en combinaison avec un activateur tissulaire du plasminogène et/ou une procédure de thrombectomie pour traiter un accident vasculaire cérébral
|
US20220111031A1
(en)
|
2018-10-22 |
2022-04-14 |
Evaxion Biotech Aps |
Vaccines targeting M. catharrhalis
|
US20220098256A1
(en)
|
2018-11-30 |
2022-03-31 |
Tokushima University |
Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2
|
WO2020171889A1
(fr)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocage de l'accumulation des lipides ou de l'inflammation dans la maladie oculaire thyroïdienne
|
EP3931206A1
(fr)
|
2019-02-27 |
2022-01-05 |
Evaxion Biotech ApS |
Vaccins ciblant h. influenzae
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
EP3999546A1
(fr)
|
2019-07-19 |
2022-05-25 |
The Children's Hospital of Philadelphia |
Récepteurs antigéniques chimériques contenant des domaines de liaison au glypicane 2
|
CN115175680A
(zh)
|
2019-10-18 |
2022-10-11 |
加利福尼亚大学董事会 |
Plxdc激活剂及其用于治疗血管病症的用途
|
KR102237349B1
(ko)
|
2019-10-23 |
2021-04-07 |
한국과학기술연구원 |
니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
|
WO2021113644A1
(fr)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer
|
WO2021140123A1
(fr)
|
2020-01-06 |
2021-07-15 |
Evaxion Biotech Aps |
Vaccins ciblant neisseria gonorrhoeae
|
CA3173567A1
(fr)
|
2020-03-02 |
2021-09-10 |
Tenaya Therapeutics, Inc. |
Regulation de vecteur genique au moyen de micro-arn exprimes par des cardiomyocytes
|
EP4127148A1
(fr)
|
2020-03-25 |
2023-02-08 |
Erasmus University Rotterdam Medical Center |
Système rapporteur pour imagerie de radionucléides
|
JP2023537558A
(ja)
|
2020-05-27 |
2023-09-04 |
アンチオン バイオサイエンシーズ エスアー |
目的の抗原にcar t細胞をリダイレクトするためのアダプター分子
|
WO2021243203A1
(fr)
|
2020-05-29 |
2021-12-02 |
FUJIFILM Cellular Dynamics, Inc. |
Bicouche d'épithélium pigmentaire rétinien et de photorécepteurs et son utilisation
|
CN116033912A
(zh)
|
2020-05-29 |
2023-04-28 |
富士胶片细胞动力公司 |
视网膜色素上皮和感光器双细胞聚集物及其使用方法
|
WO2022053130A1
(fr)
|
2020-09-09 |
2022-03-17 |
Sid Alex Group, S.R.O. |
Antago-mir-155 pour le traitement des cancers induits par v-src, c-src-tyrosine kinase
|
WO2022173767A1
(fr)
|
2021-02-09 |
2022-08-18 |
University Of Houston System |
Virus oncolytique pour l'administration systémique et les activités anti-tumorales améliorées
|
US20240122865A1
(en)
|
2021-02-19 |
2024-04-18 |
Pfizer Inc. |
Methods of Protecting RNA
|
CN117242173A
(zh)
|
2021-05-03 |
2023-12-15 |
安斯泰来再生医药协会 |
产生成熟角膜内皮细胞的方法
|
BR112023022181A2
(pt)
|
2021-05-07 |
2024-02-06 |
Astellas Inst For Regenerative Medicine |
Métodos de geração de hepatócitos maduros
|
EP4347796A1
(fr)
|
2021-05-26 |
2024-04-10 |
Fujifilm Cellular Dynamics, Inc. |
Procédés pour empêcher le silençage rapide de gènes dans des cellules souches pluripotentes
|
CA3224564A1
(fr)
|
2021-07-05 |
2023-01-12 |
Andreas Holm MATTSSON |
Vaccins ciblant neisseria gonorrhoeae
|
WO2023089556A1
(fr)
|
2021-11-22 |
2023-05-25 |
Pfizer Inc. |
Réduction du risque de mimétisme antigènique dans des médicaments immunogènes
|
WO2023144779A1
(fr)
|
2022-01-28 |
2023-08-03 |
Pfizer Inc. |
Variants d'antigène de coronavirus
|
WO2023178191A1
(fr)
|
2022-03-16 |
2023-09-21 |
University Of Houston System |
Système d'administration de gène hsv persistant
|
GB202205265D0
(en)
|
2022-04-11 |
2022-05-25 |
Mogrify Ltd |
Cell conversion
|
GB202206507D0
(en)
|
2022-05-04 |
2022-06-15 |
Antion Biosciences Sa |
Expression construct
|
WO2023213393A1
(fr)
|
2022-05-04 |
2023-11-09 |
Evaxion Biotech A/S |
Variants de protéine staphylococcique et parties tronquées
|
WO2023239940A1
(fr)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Variants de fc igg1 sélectifs de fcriib modifiés et leurs utilisations
|
WO2024006911A1
(fr)
|
2022-06-29 |
2024-01-04 |
FUJIFILM Holdings America Corporation |
Astrocytes dérivés d'ipsc et leurs procédés d'utilisation
|